Structured Deposits - The company has subscribed to structured deposits with China Merchants Bank and Xiamen International Bank a total of 40 times from January 14, 2022, to July 4, 2024[5]. - The annual interest rate for the structured deposits linked to the RMB gold benchmark price ranges from 1.65% to 3.0%[5]. - The company redeemed all structured deposits as of the announcement date[3]. - The subscription amounts for structured deposits include RMB 50 million, RMB 100 million, and RMB 400 million in various transactions[6]. - The structured deposits have a product duration ranging from 15 days to 3 months[5]. - The company has a cash and treasury management strategy involving these structured deposits[3]. - The structured deposits are characterized by low risk, high liquidity, and low volatility[5]. - The company has no penalties for early termination or redemption of the structured deposits[5]. - The structured deposits are flexible for redemption without incurring penalties, subject to interest calculation[5]. - The company aims to enhance its financial management through these structured deposits[3]. - The company has subscribed to structured deposits from Xiamen International Bank a total of 9 times from August 3, 2023, to July 4, 2024[15]. - The total amount of structured deposits subscribed by the company from Xiamen International Bank is 1,000,000,000 RMB[1]. - The company has redeemed all remaining structured deposits from Xiamen International Bank as of the announcement date[14]. - The structured deposits are characterized by capital protection, high liquidity, and low volatility, providing better returns compared to traditional deposits[10]. - The company aims to optimize the return on idle cash while maintaining sufficient liquidity through these structured deposits[10]. - The company has implemented appropriate internal control procedures to ensure that the subscriptions do not affect the adequacy of operating funds[10]. - The terms of the structured deposits are considered fair and reasonable, aligning with the overall interests of the company and its shareholders[10]. Internal Control and Compliance - The internal control review identified potential risks and areas for improvement in the group's investment and cash management processes[37]. - The company has implemented remedial measures to prevent future non-compliance with listing rules, including a gap analysis of internal control procedures[34]. - The internal control consultant's review included examining relevant internal control policies and procedures[38]. - The company has fully adopted and implemented the recommendations from the internal control review[41]. - The company has acknowledged the failure to comply with disclosure requirements for structured deposit subscriptions[42]. - The maximum applicable percentage for subscriptions to structured deposits from Xiamen International Bank was above 5% but below 25%, thus constituting a disclosable transaction[23]. - The company has fully implemented the recommendations for improving investment management internal reporting and approval processes[47]. - The company will conduct quarterly reviews of the use of funds raised from the initial public offering (IPO), including explanations for any discrepancies between planned and actual usage[45]. - The company has appointed a compliance advisor to assist in adhering to listing rules until the financial results for the fiscal year ending December 31, 2025, are compliant with the relevant regulations[50]. - The company aims to enhance the management guidelines for the funds raised from the IPO[53]. - The company plans to provide more training regarding the classification of its investment nature and related disclosure requirements under listing rules[48]. - The company will monitor ongoing investments through regular reviews every two months or quarterly and report on the status of projects[48]. - The company has adopted measures to clarify and define the scope of investment and financial products in its policies[47]. - The company is committed to improving the filing and record-keeping related to investment activities[48]. - The company has received shareholder approval for the use of IPO funds as disclosed in the interim results announcement[62]. - The company will ensure that the management of idle IPO funds is distinct from general cash and treasury management activities[45]. - The company has established a management framework for investment, cash, and financial management related to the IPO proceeds[64]. - Key control points and major risks have been identified through interviews with relevant management personnel[65]. - Detailed guidelines for the use and management of IPO proceeds have been developed, with a regular review process established[67]. - Approval procedures have been set for financial personnel to consult legal departments when evaluating financial products[67]. - A program has been implemented requiring employees to consult external auditors and legal advisors to ensure compliance with disclosure regulations[67]. - The company recommends providing regular training to financial personnel to enhance their understanding of internal control procedures and disclosure regulations[68]. - The company has fully adopted and implemented the aforementioned recommendations[68]. Technology and Subsidiaries - The company focuses on using AI technology for early detection and diagnosis of chronic eye diseases and health risk assessment[18]. - Beijing Intelligent Technology, a subsidiary of the company, is involved in the sale of hardware and provision of AI-based software solutions[18]. Financial Assets - As of June 30, 2024, the fair value of financial assets measured at fair value through profit or loss was RMB 445.8 million, primarily due to the purchase of several wealth management products[31]. - The company purchased a note from Ideal Venture LP with a principal amount of USD 9 million, which is capital-protected and allows early redemption without penalties[31]. - 39 out of 40 subscription items for structured deposits from China Merchants Bank exceeded 5% but were below 25%, thus requiring disclosure under listing rules[28].
鹰瞳科技-B(02251) - 2024 - 中期业绩